In this trial, the authors identified homologous domains shared by EGFR, HER2 and HER3, and tested the immunogenicity and the clinical potential of EGFR/HER2 specific peptide-based vaccination in dogs with ErbB/Her2-overexpressing tumors, including OSA. The gene discussed is ERBB2; the disease is obstructive sleep apnea syndrome.